ALEXANDRA LUCAS, M.D.
Osteopathic Medicine at Archer Rd, Gainesville, FL

7745396, Jun 29, 2010

Sep 7, 2007

11/899680

Alexandra Lucas - Gainesville FL, US

Viron Therapeutics Inc. - London

C07K 14/00

514 2, 530350, 435183

Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided. The compositions and methods of the present invention are useful for treating and preventing recurrence of numerous cardiovascular diseases and injuries.

2012027, Oct 25, 2012

Oct 21, 2010

13/496408

Alexandra R. Lucas - Gainesville FL, US

Viron Therapeutics Inc. - London ON

A61K 38/55, A61P 9/10, A61P 9/00

514 164

Methods of treating a patient receiving a cardiac stent implant including the steps of: (i) monitoring the circulating level of Tn I or CK-MB in the patient; and (ii) administering SERP-I to the patient in an amount sufficient to prevent the circulating level of Tn I or CK-MB from exceeding a specified threshold for the first 24 hours following implantation are disclosed. A specified value of SERP-I is sufficient for preventing circulating level of Tn I or CK-MB from exceeding a specified threshold during the first 24 hours following implantation. The dosing regime of SERP-I to the patient starting within 24 hours of post-implantation is also disclosed.

2011028, Nov 24, 2011

Jun 21, 2007

12/993191

D. Grant McFadden - Gainsville FL, US
Alexandra R. Lucas - Gainesville FL, US
John W. Barrett - London, CA

A61K 38/16, C12N 15/63, C12N 5/10, C12P 21/00, C07K 14/065, A61P 29/00, A61P 11/00, A61P 27/14, A61P 17/00, A61P 11/06, A61P 9/00, A61P 9/10, A61P 25/00, A61P 3/10, A61P 13/12, A61P 35/02, A61P 25/28, A61P 19/02, A61P 7/06, A61P 35/00, C07H 21/00, C07K 19/00, A61K 31/7088, A61P 37/02, A61P 17/10, A61P 37/04, A61P 11/02, A61P 37/06, A61P 1/16, A61P 1/18, A61P 1/00, A61P 43/00, C12N 5/09

514 14, 435375, 4353201, 435325, 435 691, 530350, 514 11, 514 212, 514 15, 514 208, 514 187, 514 17, 514 164, 514 19, 514 177, 514 69, 514 154, 514 196, 514 179, 514 168, 514 135, 514 166, 514 73, 514 192, 514 193, 514 194, 514 195, 536 2372, 536 234, 514 44 R

The invention features polypeptide and polynucleotide sequences based on the 134R sequence. In some embodiments, these sequences include a heterologous signal sequence, such as the myxoma virus T7 signal sequence. The invention also features methods for treating immunological disorders and neoplasms (e.g., cancer) using the polypeptides and nucleotides described herein. Finally, the invention features fusion proteins including the myxoma virus T7 signal sequence.